Focus: Beta Bionics is a public biotech company focused on artificial pancreas technology, specifically the iLet Bionic Pancreas system for diabetes management. With 1-50 employees and $65M in FY 2025 revenue, it operates as a specialized medical device and software company in the gastroenterology/endocrinology space.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
8 added, 11 removed. Backfill posture.
Best suited for commercial, regulatory, or supply chain professionals seeking high-growth opportunity; less attractive for R&D scientists due to narrow pipeline focus and financial burn rate.
Phase 3 lead program with potential regulatory approval pathway; addresses underserved CF-related diabetes population.
Help build intelligence for Beta Bionics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Beta Bionics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Phase 2/3 program expanding addressable market to broader Type 1 diabetes population; dual-hormone formulation differentiates from competitors.
Phase 2 program supporting iLet platform integration; proprietary insulin formulation may enable device-drug synergies.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo